Selected article for: "active cancer and admission time"

Author: Smith, Maria; Lara, Olivia D.; O'Cearbhaill, Roisin; Knisely, Anne; McEachron, Jennifer; Gabor, Lisa; Carr, Caitlin; Blank, Stephanie; Prasad-Hayes, Monica; Frey, Melissa; Jee, Justin; Fehniger, Julia; Wang, Yuyan; Lee, Yi-chun; Isani, Sara; Wright, Jason D.; Pothuri, Bhavana
Title: Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection
  • Cord-id: vt7cw4rb
  • Document date: 2020_9_25
  • ID: vt7cw4rb
    Snippet: Objective: Elevated inflammatory markers are predictive of COVID-19 infection severity and mortality. It is unclear if these markers are associated with severe infection in patients with cancer due to underlying tumor related inflammation. We sought to further understand the inflammatory response related to COVID-19 infection in patients with gynecologic cancer. Methods: Patients with a history of gynecologic cancer hospitalized for COVID-19 infection with available laboratory data were identifi
    Document: Objective: Elevated inflammatory markers are predictive of COVID-19 infection severity and mortality. It is unclear if these markers are associated with severe infection in patients with cancer due to underlying tumor related inflammation. We sought to further understand the inflammatory response related to COVID-19 infection in patients with gynecologic cancer. Methods: Patients with a history of gynecologic cancer hospitalized for COVID-19 infection with available laboratory data were identified. Admission laboratory values and clinical outcomes were abstracted from electronic medical records. Severe infection was defined as infection requiring ICU admission, mechanical ventilation, or resulting in death. Results: 86 patients with gynecologic cancer were hospitalized with COVID-19 infection with a median age of 68.5 years (interquartile range (IQR), 59.0–74.8). Of the 86 patients, 29 (33.7%) patients required ICU admission and 25 (29.1%) patients died of COVID-19 complications. Fifty (58.1%) patients had active cancer and 36 (41.9%) were in remission. Patients with severe infection had significantly higher ferritin (median 1163.0 vs 624.0 ng/mL, p < 0.01), procalcitonin (median 0.8 vs 0.2 ng/mL, p < 0.01), and C-reactive protein (median 142.0 vs 62.3 mg/L, p = 0.02) levels compared to those with moderate infection. White blood cell count, lactate, and creatinine were also associated with severe infection. D-dimer levels were not significantly associated with severe infection (p = 0.20). Conclusions: The inflammatory markers ferritin, procalcitonin, and CRP were associated with COVID-19 severity in gynecologic cancer patients and may be used as prognostic markers at the time of admission.

    Search related documents:
    Co phrase search for related documents
    • absolute neutrophil count and active infection: 1, 2, 3
    • absolute neutrophil count and active malignancy: 1, 2
    • absolute neutrophil count and acute ards respiratory distress syndrome: 1, 2
    • absolute neutrophil count and acute phase: 1, 2, 3, 4, 5, 6
    • absolute neutrophil count and admission time: 1, 2, 3
    • absolute neutrophil count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active cancer and acute ards respiratory distress syndrome: 1, 2
    • active cancer and acute phase: 1, 2
    • active cancer and admission time: 1
    • active cancer and lymphocyte count: 1, 2, 3
    • active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • active infection and acute phase: 1, 2, 3, 4, 5, 6, 7
    • active infection and admission time: 1, 2
    • active infection and lymphocyte count: 1, 2, 3
    • active malignancy and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and admit patient: 1
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and admission time: 1, 2, 3, 4, 5, 6, 7, 8